Exosomes Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Qiagen, Thermo Fisher Scientific, Illumina, Takara Bio, Malvern Instruments

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Exosomes pipeline constitutes 66+ key companies continuously working towards developing 75+ Exosomes treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Exosomes Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.


Exosomes Pipeline Insight, 2024 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Exosomes Market.


Some of the key takeaways from the Exosomes Pipeline Report: 

Companies across the globe are diligently working toward developing novel Exosomes treatment therapies with a considerable amount of success over the years. 

Exosomes companies working in the treatment market are Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, Endosome Therapy StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, Aegle Therapeutics, Regeneus, Direct Biologics, Capricor Therapeutics, and others, are developing therapies for the Exosomes treatment 

Emerging Exosomes therapies in the different phases of clinical trials are- ExoCoVac, COYA 201, EV-101, StemXO, BRE AD01, ILB 202, Zofin, exoSTING, AGLE 102, Progenza, ExoFl, CAP-1002, and others are expected to have a significant impact on the Exosomes market in the coming years.   

In January 2024, Aruna Bio, Inc., a trailblazer in the advancement of therapeutic treatments based on neural exosomes for neurodegenerative diseases, announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the Investigational New Drug (IND) application for its leading program, AB126. This regulatory approval sets the stage for the initiation of the Phase 1b/2a clinical trial focusing on acute ischemic stroke, anticipated to commence in the first half of 2024. AB126, characterized as an unaltered neural-derived exosome, possesses intrinsic capabilities to traverse the blood-brain barrier and exhibits indications of anti-inflammatory and neuroprotective properties.

In July 2022, Cells for Cells, a biotechnology company in the clinical stage, known for its work in developing allogeneic stem cell and stem-cell-derived treatments for significant chronic diseases, has reported a 6-month follow-up on the innovative clinical data obtained from the initial administration of a therapy produced from exosomes for osteoarthritis.

In April 2022, Global Stem Cells Group (GSCG) has introduced a new product featuring advanced lyophilized exosome technology. The innovative product line from Global Stem Cells Group includes anti-aging solutions designed to rejuvenate cells and tissues within the body.

In June 2022, Capricor Inc. has commenced a clinical trial titled “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Human Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy” known as HOPE-3. This multi-center trial is designed to be randomized, double-blind, and placebo-controlled, with a focus on assessing the safety and effectiveness of CAP-1002, a cell therapy. The trial is specifically targeting participants with Duchenne muscular dystrophy (DMD) who exhibit impaired skeletal muscle function.

In February 2022, Capricor Therapeutics, a biotechnology firm working on the developmental treatment CAP-1002 for individuals with Duchenne muscular dystrophy (DMD), has revealed a collaboration with Nippon Shinyaku Co (NS Pharma) for the exclusive commercialization and distribution of the therapy in the United States. This announcement comes in anticipation of the commencement of the phase 3 HOPE-3 study (NCT05126758).


Exosomes Overview

Exosomes are small membrane-bound vesicles that are released by cells into the extracellular space. These vesicles play a crucial role in intercellular communication by transporting various biomolecules, including proteins, lipids, and nucleic acids, between cells. Exosomes are a type of extracellular vesicle, and they are part of the body’s natural communication system.


Get a Free Sample PDF Report to know more about Exosomes Pipeline Therapeutic Assessment-



Emerging Exosomes Drugs Under Different Phases of Clinical Development Include:

ExoCoVac: Innovex Therapeutics

COYA 201: Coya Therapeutics

EV-101: EV Therapeutics

StemXO: Endosome Therapy StemXO Therapeutics

BRE AD01: Brexogen

ILB 202: ILIAS Biologics

Zofin: Organicell Regenerative Medicine

exoSTING: Codiak BioSciences

AGLE 102: Aegle Therapeutics

Progenza: Regeneus

ExoFlo: Direct Biologics

CAP-1002: Capricor Therapeutics


Exosomes Route of Administration

Exosomes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 












Exosomes Molecule Type

Exosomes Products have been categorized under various Molecule types, such as



Small molecule


Exosomes Pipeline Therapeutics Assessment

Exosomes Assessment by Product Type

Exosomes By Stage and Product Type

Exosomes Assessment by Route of Administration

Exosomes By Stage and Route of Administration

Exosomes Assessment by Molecule Type

Exosomes by Stage and Molecule Type


DelveInsight’s Exosomes Report covers around 75+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I)

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration


Further Exosomes product details are provided in the report. Download the Exosomes pipeline report to learn more about the emerging Exosomes therapies


Some of the key companies in the Exosomes Therapeutics Market include:

Key companies developing therapies for Exosomes are – Qiagen, Thermo Fisher Scientific Inc., Illumina Inc., Takara Bio Inc., Malvern Instruments Ltd, Abcam PLC, Evox Therapeutics, Danaher Corporation (Beckman Coulter Inc.), Hologic Inc., Fujifilm Holdings Corporation, Lonza Group Ltd, JSR Corporation (MBL International), Miltenyi Biotec, Bio-Techne (Novus Biologicals), Capricor Therapeutics Inc., and others.


Exosomes Pipeline Analysis:

The Exosomes pipeline report provides insights into 

The report provides detailed insights about companies that are developing therapies for the treatment of Exosomes with aggregate therapies developed by each company for the same.

It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Exosomes Treatment.

Exosomes key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

Exosomes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Exosomes market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.


Download Sample PDF Report to know more about Exosomes drugs and therapies


Exosomes Pipeline Market Drivers

Exosomes as an emerging messenger in diagnostics, a rise in exosome-based drug development, exosomes as a promising tool in the field of nanomedicine are some of the important factors that are fueling the Exosomes Market.


Exosomes Pipeline Market Barriers

However, lack of standardized techniques for the isolation and purification of exosomes, lack of scalable manufacturing processes and other factors are creating obstacles in the Exosomes Market growth.


Scope of Exosomes Pipeline Drug Insight    

Coverage: Global

Key Exosomes Companies: Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, Endosome Therapy StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, Aegle Therapeutics, Regeneus, Direct Biologics, Capricor Therapeutics, and others

Key Exosomes Therapies: ExoCoVac, COYA 201, EV-101, StemXO, BRE AD01, ILB 202, Zofin, exoSTING, AGLE 102, Progenza, ExoFl, CAP-1002, and others

Exosomes Therapeutic Assessment: Exosomes current marketed and Exosomes emerging therapies

Exosomes Market Dynamics: Exosomes market drivers and Exosomes market barriers 


Request for Sample PDF Report for Exosomes Pipeline Assessment and clinical trials


Table of Contents

1. Exosomes Report Introduction

2. Exosomes Executive Summary

3. Exosomes Overview

4. Exosomes- Analytical Perspective In-depth Commercial Assessment

5. Exosomes Pipeline Therapeutics

6. Exosomes Late Stage Products (Phase II/III)

7. Exosomes Mid Stage Products (Phase II)

8. Exosomes Early Stage Products (Phase I)

9. Exosomes Preclinical Stage Products

10. Exosomes Therapeutics Assessment

11. Exosomes Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Exosomes Key Companies

14. Exosomes Key Products

15. Exosomes Unmet Needs

16 . Exosomes Market Drivers and Barriers

17. Exosomes Future Perspectives and Conclusion

18. Exosomes Analyst Views

19. Appendix

20. About DelveInsight


About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Stay up to date
Register now to get updates on promotions and coupons

Shopping cart